Reported Earnings • May 06
First quarter 2026 earnings: EPS and revenues miss analyst expectations First quarter 2026 results: US$2.81 loss per share (down from US$0.001 profit in 1Q 2025). Revenue: US$969.2m (down 7.2% from 1Q 2025). Net loss: US$389.9m (down US$390.0m from profit in 1Q 2025). Revenue missed analyst estimates by 6.4%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to stay flat during the next 3 years compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance. 속보 • May 06
Perrigo Faces Formula Probe and Production Challenges as Earnings Preview Approaches Perrigo is under investigation over alleged misconduct in its infant formula business, including claims of misleading disclosures and underinvestment in facilities acquired from Nestlé.
The company faces securities litigation tied to alleged overstated financial results, higher remediation and production costs, and lowered financial guidance related to the infant formula segment.
Perrigo plans to report Q1 2026 results on May 6, with analysts expecting EPS of $0.31 on about US$1.03b of revenue and pointing to pressure from pricing, competition, and operational issues.
For investors, the key tension is between the legal and operational overhang in infant formula and the upcoming earnings update. The internal investigation and the strategic review of the formula segment suggest that management is reassessing how this business fits with the broader portfolio and what it may cost to address existing issues.
Analyst EPS estimates have been cut by 41.5% over the past 90 days, which indicates reduced confidence in near-term profitability. The Q1 report and conference call are expected to focus on three areas: the scale and timing of remediation spending in infant formula, any change in guidance tied to that segment, and how pricing and competition are affecting margins across Perrigo’s consumer health operations. The clarity of management’s commentary on these points may matter as much as the headline numbers. Declared Dividend • May 01
Fourth quarter dividend of US$0.29 announced Dividend of US$0.29 is the same as last year. Ex-date: 29th May 2026 Payment date: 5th June 2026 Dividend yield will be 9.7%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (107% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. 공시 • Apr 22
Perrigo Company plc to Report Q1, 2026 Results on May 06, 2026 Perrigo Company plc announced that they will report Q1, 2026 results Pre-Market on May 06, 2026 공시 • Mar 23
Perrigo Company plc, Annual General Meeting, Apr 30, 2026 Perrigo Company plc, Annual General Meeting, Apr 30, 2026. Location: 25 north wall quay, dublin, d01 h104, ireland., United States New Risk • Feb 26
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. Cash payout ratio: 107% Dividend yield: 8.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 26
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: US$10.13 loss per share (further deteriorated from US$1.17 loss in FY 2024). Revenue: US$4.25b (down 2.8% from FY 2024). Net loss: US$1.40b (loss widened US$1.24b from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance. 공시 • Feb 26
Perrigo Company plc Provides Earnings Targets for the Fiscal Year 2026 Perrigo Company plc provided earnings targets for the fiscal year 2026. For the year, the company total net sales outlook of -5.5% to -1.5%, versus the prior year. Declared Dividend • Feb 22
Third quarter dividend of US$0.29 announced Dividend of US$0.29 is the same as last year. Ex-date: 2nd March 2026 Payment date: 24th March 2026 Dividend yield will be 7.7%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (61% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. 공시 • Feb 20
Perrigo Announces Quarterly Dividend, Payable on March 24, 2026 Perrigo Company plc announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on March 24, 2026, to shareholders of record on March 2, 2026. 공시 • Feb 13
Perrigo Company plc to Report Q4, 2025 Results on Feb 26, 2026 Perrigo Company plc announced that they will report Q4, 2025 results Pre-Market on Feb 26, 2026 Upcoming Dividend • Nov 21
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 28 November 2025. Payment date: 16 December 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 9.5%. Within top quartile of American dividend payers (4.6%). Higher than average of industry peers (2.2%). 공시 • Nov 18
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit on Behalf of Perrigo Company plc Shareholders Glancy Prongay & Murray LLP (GPM), announced that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned French v. Perrigo Company plc, et al., Case No. 1:25-cv-09596, on behalf of persons and entities that purchased or otherwise acquired Perrigo Company plc (Perrigo or the Company) securities between February 27, 2023 and November 4, 2025, inclusive (the Class Period). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act). Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs; (2) that Perrigo needed to make substantial capital and operational expenditures above the Company’s outwardly stated cost estimates to remediate the infant formula business; (3) that there were significant manufacturing deficiencies in the facility for the Company’s infant formula business; (4) that, as a result of the foregoing, the Company’s financial results, including earnings and cash flow, were overstated; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Price Target Changed • Nov 06
Price target decreased by 25% to US$24.50 Down from US$32.50, the current price target is an average from 4 analysts. New target price is 64% above last closing price of US$14.93. Stock is down 45% over the past year. The company is forecast to post earnings per share of US$0.91 next year compared to a net loss per share of US$1.17 last year. Reported Earnings • Nov 06
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: US$0.092 (up from US$0.13 loss in 3Q 2024). Revenue: US$1.04b (down 4.1% from 3Q 2024). Net income: US$12.7m (up US$30.3m from 3Q 2024). Profit margin: 1.2% (up from net loss in 3Q 2024). Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 67%. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. 공시 • Nov 05
Perrigo Company plc Updates Earnings Guidance for the Full Year of 2025 Perrigo Company plc updated earnings guidance for the full year of 2025. For the year, the company now expects net sales growth to be between negative 2.5% to negative 3.0% due primarily to infant formula industry dynamics and soft OTC consumption trends. Declared Dividend • Nov 02
Second quarter dividend of US$0.29 announced Shareholders will receive a dividend of US$0.29. Ex-date: 28th November 2025 Payment date: 16th December 2025 Dividend yield will be 5.6%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (65% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. 공시 • Oct 29
Perrigo Company plc Declares Quarterly Dividend, Payable on December 16, 2025 Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on December 16, 2025, to shareholders of record on November 28, 2025. 공시 • Oct 22
Perrigo Company plc to Report Q3, 2025 Results on Nov 05, 2025 Perrigo Company plc announced that they will report Q3, 2025 results on Nov 05, 2025 Price Target Changed • Oct 16
Price target decreased by 7.6% to US$33.50 Down from US$36.25, the current price target is an average from 4 analysts. New target price is 56% above last closing price of US$21.53. Stock is down 14% over the past year. The company is forecast to post earnings per share of US$0.38 next year compared to a net loss per share of US$1.17 last year. Upcoming Dividend • Aug 22
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 29 August 2025. Payment date: 16 September 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 4.7%. Within top quartile of American dividend payers (4.5%). Higher than average of industry peers (2.6%). Reported Earnings • Aug 07
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: US$0.004 loss per share (improved from US$0.77 loss in 2Q 2024). Revenue: US$1.06b (flat on 2Q 2024). Net loss: US$500.0k (loss narrowed 100% from 2Q 2024). Profit margin: 0% (up from net loss in 2Q 2024). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. 공시 • Aug 06
Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal Year 2025 Perrigo Company plc reaffirmed earnings guidance for the fiscal year 2025. For the period, Company expects Reported net sales growth of 0% to 3%. Organic net sales growth of 1.5% to 4.5%. Declared Dividend • Aug 03
First quarter dividend of US$0.29 announced Shareholders will receive a dividend of US$0.29. Ex-date: 29th August 2025 Payment date: 16th September 2025 Dividend yield will be 4.3%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not adequately covered by cash flows (93% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. 공시 • Jul 31
Perrigo Company plc Declares Quarterly Dividend, Payable on September 16, 2025 Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on September 16, 2025, to shareholders of record on August 29, 2025. 공시 • Jul 23
Perrigo Company plc to Report Q2, 2025 Results on Aug 06, 2025 Perrigo Company plc announced that they will report Q2, 2025 results on Aug 06, 2025 Recent Insider Transactions Derivative • Jul 15
President exercised options to buy US$381k worth of stock. On the 10th of July, Patrick Lockwood-Taylor exercised 28.33k options to receive shares at no cost, then sold around 14.23k of them at US$27.27 each and kept the remainder. Since March 2025, Patrick's direct individual holding has increased from 55.87k shares to 67.26k. Company insiders have collectively bought US$505k more than they sold, via options and on-market transactions, in the last 12 months. 공시 • Jul 15
KKR & Co. Inc. (NYSE:KKR) entered into a Master Sale and Purchase Agreement to acquire Aco Hud Nordic AB and Assets related to Dermacosmetics Business of Perrigo Company plc, Perrigo Pharma Holding Nederland BV, and Perrigo Holding NV for approximately €330 million. KKR & Co. Inc. (NYSE:KKR) entered into a Master Sale and Purchase Agreement to acquire Aco Hud Nordic AB and Assets related to Dermacosmetics Business of Perrigo Company plc, Perrigo Pharma Holding Nederland BV, and Perrigo Holding NV for approximately €330 million on July 13, 2025. Under the terms of the transaction, KKR & Co. Inc will pay €210 million for the shares of Aco Hud Nordic AB and €90 million for the assets to be acquired, subject to customary adjustments for inventory, working capital, debt and cash. Additionally, KKR & Co. Inc. will pay an earnout payment of up to €27 million cash in relation to the financial performance of the ACO Brand and the Biodermal Brand in the financial years 2025, 2026, and 2027. In case of termination of transaction, KKR & Co. Inc. will pay a termination fee of €15 million.
For the period ending December 31, 2024, Aco Hud Nordic AB and the Assets related to Dermacosmetics Business of Perrigo Company plc reported total revenue of €125 million.
The transaction is subject to the satisfaction or waiver of customary closing conditions, including, among others: (1) receipt of regulatory approvals in certain jurisdictions, (2) consummation of pre-closing restructuring transactions with respect to the Target, (3) completion of works council consultation procedures in certain countries and (4) the closing of KKR’s previously announced proposed acquisition of Karo Healthcare. The expected completion of the transaction is in the first quarter of 2026. Expected net proceeds from the transaction would be directed towards previously announced capital allocation priorities, including further strengthening the Perrigo Company’s balance sheet and supporting long-term value creation.
Latham & Watkins LLP acted as legal advisor for Perrigo Company. Alvaro Membrillera, Anna Van de moortel, Ian Barratt, Natasha Smith, and Brett Ackerman of Kirkland & Ellis acted as legal advisor for KKR & Co. Inc. Greenhill & Co., Inc. acted as financial advisor for Perrigo Company. 공시 • Jul 02
Perrigo Company plc Announces Executive Changes Perrigo Company plc announced that to support this alignment, including category strategy execution, go-to-market excellence and global demand generation across all regions, Roberto Khoury has been appointed EVP and Chief Commercial Officer. Mr. Khoury has a strong track record of success leading Perrigo's CSCI business and will play a key role in aligning commercial functions with the new global category model. Mr. Khoury will assume responsibility for operating results in both CSCI and CSCA and will partner closely with David Ball, EVP and Chief Brand and Digital Officer, who is responsible for global category leadership. As part of this alignment, the roles of EVP and President CSCI and EVP and President CSCA will be discontinued. Triona Schmelter will depart the organization and be available on a consultative basis until October 31, 2025. Perrigo extends its sincere gratitude for her leadership and contributions over the past two years, including the launch of Opill which was a significant inflection point for CSCA and women's reproductive health in the U.S. 공시 • Jun 05
Perrigo Company plc Announces Executive Changes Perrigo Company plc announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Throughout his tenure, Mr. Janish played an integral role in advancing and aligning the Company's supply chain with its transformation to a consumer self-care leader and steering its Supply Chain Reinvention program, which significantly reduced portfolio complexity and improved forecast accuracy. Mr. Winterman brings more than 20 years of global supply chain and strategy leadership to Perrigo. Most recently, he served as SVP of Global Supply Chain and Strategy at AstraZeneca, overseeing a $54 billion supply chain across 5,000 SKUs. He also served as Global Head of end-to-end Supply Chain at Roche Holding AG, and prior to that in roles of increasing responsibility for technical operations strategy and supply chain performance at GSK plc. Mr. Winterman graduated with a Bachelor of Science degree in Economics from the University of Bristol. Board Change • Jun 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Kevin Egan was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 23
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 30 May 2025. Payment date: 17 June 2025. The company is not currently making a profit and its cash payout ratio is 93%. Trailing yield: 4.4%. Lower than top quartile of American dividend payers (4.8%). Higher than average of industry peers (2.8%). Reported Earnings • May 07
First quarter 2025 earnings released: EPS: US$0.001 (vs US$0.03 in 1Q 2024) First quarter 2025 results: EPS: US$0.001 (down from US$0.03 in 1Q 2024). Revenue: US$1.04b (down 3.5% from 1Q 2024). Net income: US$100.0k (down 98% from 1Q 2024). Profit margin: 0% (down from 0.4% in 1Q 2024). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 7% per year. Declared Dividend • May 04
Fourth quarter dividend of US$0.29 announced Shareholders will receive a dividend of US$0.29. Ex-date: 30th May 2025 Payment date: 17th June 2025 Dividend yield will be 4.4%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (64% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. 공시 • Apr 30
Perrigo Company plc Announces Quarterly Dividend, Payable on June 17, 2025 Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. 공시 • Apr 24
Perrigo Company plc to Report Q1, 2025 Results on May 07, 2025 Perrigo Company plc announced that they will report Q1, 2025 results on May 07, 2025 Recent Insider Transactions Derivative • Apr 11
President exercised options to buy US$281k worth of stock. On the 4th of April, Patrick Lockwood-Taylor exercised 17.84k options to receive shares at no cost, then sold around 6.45k of them at US$26.31 each and kept the remainder. Since September 2024, Patrick's direct individual holding has increased from 45.41k shares to 67.26k. Company insiders have collectively bought US$589k more than they sold, via options and on-market transactions, in the last 12 months. 공시 • Mar 12
Perrigo Company plc, Annual General Meeting, May 01, 2025 Perrigo Company plc, Annual General Meeting, May 01, 2025. Location: 70 sir john rogerson`s quay, grand canal dock, d02 r296, dublin 2 Ireland Reported Earnings • Feb 28
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: US$1.17 loss per share (further deteriorated from US$0.033 loss in FY 2023). Revenue: US$4.37b (down 6.1% from FY 2023). Net loss: US$160.7m (loss widened US$156.3m from FY 2023). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 54%. Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. 공시 • Feb 28
Perrigo Company plc Provides Earnings Targets for the Fiscal Year 2025 Perrigo Company plc provided earnings targets for the fiscal year 2025. For the year, the company targets all-in net sales growth to be between 1% to 3%. Organic net sales growth to be between 2.5% to 4.5%. Declared Dividend • Feb 23
Third quarter dividend increased to US$0.29 Dividend of US$0.29 is 5.1% higher than last year. Ex-date: 7th March 2025 Payment date: 25th March 2025 Dividend yield will be 4.4%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not adequately covered by cash flows (96% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. 공시 • Feb 20
Perrigo Company plc Increases Its Quarterly Dividend, Payable on March 25, 2025 Perrigo Company plc announced that its Board of Directors has approved a 5% increase in the Company's quarterly dividend to $0.290 per share, or $1.16 per share on an annual basis, up from $0.276 per share. This marks the 22nd consecutive year Perrigo has increased its dividend. The cash dividend is payable on March 25, 2025, to shareholders of record on March 7, 2025. 공시 • Jan 31
Perrigo Company plc to Report Q4, 2024 Results on Feb 27, 2025 Perrigo Company plc announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Feb 27, 2025 공시 • Jan 17
Perrigo Company plc Appoints Jonas Samuelson to as A Member of Board of Directors and Audit Committee and the Nominating and Governance Committee On January 15, 2025, the Board of Directors of Perrigo Company plc appointed Jonas Samuelson to serve as a member of the Company’s board of directors effective as of January 15, 2025. Mr. Samuelson will also serve on the Audit Committee and the Nominating and Governance Committee of the Board. Mr. Samuelson brings substantial CEO, CFO and Board experience from both public and private companies. Most recently, he served as President, CEO and board member of AB Electrolux, where he also previously served as CFO for the Electrolux Group. Additionally, Mr. Samuelson served as CFO and Executive Vice President for Munters AB and held leadership roles in commercial finance, treasury and business planning and analysis with General Motors and Saab Automobile AB. 공시 • Jan 06
Perrigo Company plc Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer Perrigo Company plc announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and scale. This expansion also further supports the Company's consumer-led innovation pipeline. To lead this expanded office, the Company has appointed Abbie Lennox as Executive Vice President and Chief Scientific Officer. Ms. Lennox is an experienced consumer self-care leader with a successful track record of driving regulatory excellence, product life cycle management and new product innovation across well-known consumer self-care portfolios. Ms. Lennox joins Perrigo from Bayer where she served as Executive Board Member and Chief Trust and Science Officer, responsible for leading the regulatory, medical affairs, safety and quality teams. She led multiple innovation launches – both product and claim-based – across global product categories, including cardio, digestive health, allergy, cough, cold, pain, dermatology, women's health, VMS (Vitamins, Minerals and Supplements) and Rx-to-OTC switches. Specifically, Ms. Lennox provided scientific leadership for the U.S. Rx-to-OTC switch for Astepro, emphasizing consumer-centric claims supported by robust medical insights. She also led the introduction of Rennie Gum, the first European OTC chewing gum for digestive health, by navigating rigorous clinical and registration requirements while prioritizing consumer experience. Prior to her time at Bayer, she served in regulatory affairs leadership roles with Reckitt Benckiser, where she advanced their regulatory approach to pipeline delivery across multiple health and wellness brands. Ms. Lennox holds a First Class BSc (Honors) degree in Biomedical Science and Chemistry from De Montfort University. Alison Ives, who previously served as Chief Scientific Officer, has been appointed to lead a newly formed Disruptive Growth Team focused on identifying and pursuing emerging growth opportunities through category disruption and entering new markets. After successfully serving as Perrigo's Chief Scientific Officer, along with more than 20 years of experience in science-focused roles, Ms. Ives has deep expertise to unlock emerging growth opportunities. Recent Insider Transactions • Dec 11
Independent Director recently sold US$497k worth of stock On the 9th of December, Jeffrey Kindler sold around 18k shares on-market at roughly US$28.27 per share. This transaction amounted to 76% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.5m more than they bought in the last 12 months. Upcoming Dividend • Nov 22
Upcoming dividend of US$0.28 per share Eligible shareholders must have bought the stock before 29 November 2024. Payment date: 17 December 2024. The company is not currently making a profit and its cash payout ratio is 96%. Trailing yield: 4.1%. Lower than top quartile of American dividend payers (4.3%). Higher than average of industry peers (2.5%). New Risk • Nov 07
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. Cash payout ratio: 96% Dividend yield: 4.1% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 96% Minor Risk Significant insider selling over the past 3 months (US$1.6m sold). Reported Earnings • Nov 07
Third quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 profit in 3Q 2023) Third quarter 2024 results: US$0.13 loss per share (down from US$0.11 profit in 3Q 2023). Revenue: US$1.09b (down 3.2% from 3Q 2023). Net loss: US$17.6m (down 214% from profit in 3Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. 공시 • Nov 07
Perrigo Company plc Provides Revenue Guidance for the Fiscal Year 2024 Perrigo Company plc provided revenue guidance for the fiscal year 2024. For the year, the company expects organic net sales and reported net sales outlooks towards the lower end of its previously stated ranges of organic net sales growth versus the prior year of -3% to -1% and reported net sales growth versus the prior year of -5% to -3%. The Company continues to expect gross and operating margin expansion compared to the prior year. Declared Dividend • Nov 06
Second quarter dividend of US$0.28 announced Shareholders will receive a dividend of US$0.28. Ex-date: 29th November 2024 Payment date: 17th December 2024 Dividend yield will be 4.0%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (64% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. 공시 • Nov 02
Perrigo Company plc Announces Quarterly Dividend, Payable on December 17, 2024 Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on December 17, 2024, to shareholders of record on November 29, 2024. 공시 • Oct 23
Perrigo Company plc to Report Q3, 2024 Results on Nov 06, 2024 Perrigo Company plc announced that they will report Q3, 2024 results on Nov 06, 2024 공시 • Sep 04
Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary Perrigo Company plc announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry. Mr. Atkinson joins Perrigo after a successful career at Haleon plc and its prior parent, GSK plc, most recently serving as Interim General Counsel for Haleon. During his 20-plus year combined tenure at Haleon/GSK, Mr. Atkinson successfully advised across numerous transactions and integrations, including the creation of Haleon and subsequent separation from its parent shareholders GSK and Pfizer. He has also served as global head of corporate legal and was lead counsel for various parts of the self-care business, including supply chain, R&D and innovation, business development, and intellectual property. This included managing the lifecycle of regulated healthcare products, advising GSK's largest self-care business and providing counsel for product development, including leading the switch for Flonase® to over-the-counter status. He obtained his law degree from University College London. Todd Kingma, who came out of retirement to serve as Interim Executive Vice President, General Counsel & Secretary, will work with Mr. Atkinson through a transitionary period. Mr. Kingma's intimate knowledge of Perrigo and its global team will allow for a highly seamless transition. Upcoming Dividend • Aug 23
Upcoming dividend of US$0.28 per share Eligible shareholders must have bought the stock before 30 August 2024. Payment date: 17 September 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 3.8%. Lower than top quartile of American dividend payers (4.4%). Higher than average of industry peers (2.1%). Recent Insider Transactions • Aug 23
Advisor recently sold US$969k worth of stock On the 20th of August, Svend Andersen sold around 35k shares on-market at roughly US$27.69 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$282k more than they sold in the last 12 months. 공시 • Aug 19
Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer Perrigo Company plc announced the appointment of Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer. In this newly created position, Dr. Ball will be responsible for an enterprise-wide marketing strategy that incorporates deep understanding of consumer needs and translates those into winning brand strategies, tactics, and actions. He will also evaluate untapped market opportunities and develop strategies to scale the Company's brand-building efforts. Dr. Ball brings over 15 years of global consumer goods experience, spanning various commercial roles, including brand management, marketing, innovation, and research and development. He joins Perrigo from Bayer Consumer Healthcare, where he served as General Manager and Vice President of Marketing for the Digestive Health business in North America, achieving record financial performance. He also played a key role in Bayer's acquisition of a direct-to-consumer healthcare technology company and helped establish a transformative "white space" incubator group. Prior to Bayer, Dr. Ball spent a decade at Procter and Gamble in leadership positions across multiple business units and functions. Dr. Ball holds a PhD in Biophysics and Genetics from Sheffield University in England, which adds a unique dimension to his consumer goods expertise. His scientific background, combined with his experience in biotechnology, provides a valuable perspective on innovation and sustainable practices. Declared Dividend • Aug 05
Second quarter dividend of US$0.28 announced Shareholders will receive a dividend of US$0.28. Ex-date: 30th August 2024 Payment date: 17th September 2024 Dividend yield will be 4.0%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (64% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Reported Earnings • Aug 04
Second quarter 2024 earnings released: US$0.77 loss per share (vs US$0.066 profit in 2Q 2023) Second quarter 2024 results: US$0.77 loss per share (down from US$0.066 profit in 2Q 2023). Revenue: US$1.07b (down 11% from 2Q 2023). Net loss: US$105.7m (down US$114.6m from profit in 2Q 2023). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. 
